Regorafenib (BAY 73-4506)

Regorafenib (BAY 73-4506) is an inhibitor of RAF and RET and related targets used in studies of MAPK / ERK Signaling and Autophagy. In practice, this places the compound in experiments that measure mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and autophagic flux, lysosomal turnover, and stress adaptation in angiogenesis, autophagy, and cancer models.

By inhibiting RAF and RET and related targets, Regorafenib (BAY 73-4506) can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and autophagic flux, lysosomal turnover, and stress adaptation. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In angiogenesis, autophagy, and cancer models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving RAF and RET and related targets
• Pathway perturbation studies connected to MAPK / ERK Signaling and Autophagy
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, Regorafenib (BAY 73-4506) is appropriate when a defined chemical perturbant is needed to connect RAF and RET and related targets with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in angiogenesis, autophagy, and cancer models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.